Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development of the former’s ...

AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical ...

Learn about different types of eczema, symptoms, treatment options, and how to differentiate from other skin conditions.

Shares of Amgen Inc. (NASDAQ:AMGN – Get Free Report) have earned a consensus recommendation of “Hold” from the twenty-four ...

Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties ...

When your skin is red, itchy, and irritated, it could be a rash or it might be hives. We spoke with experts to learn how to ...

Robert Sidbury MD, MPH explored the “long list” of treatment options in atopic dermatitis and how the treatment landscape has changed as a result in a video interview with Healio.“So long list – I ...

Those yellowish and thickened toenails could mean you have an infection with a toenail fungus. Here are the types, symptoms, ...

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.